ACTH 4-10

Memory Consolidation and Attention

The foundational research on ACTH 4-10 demonstrated effects on conditioned behavior in rodents. De Wied's original experiments showed that ACTH 4-10 delayed the extinction of pole-jumping avoidance behavior — animals continued to perform a learned avoidance response for longer periods when treated with the peptide. This effect was interpreted as enhanced consolidation of the memory trace rather than increased motivation or anxiety.

"ACTH 4-10 facilitated acquisition and delayed extinction of conditioned avoidance behavior in hypophysectomized rats, demonstrating that the behavioral effects of ACTH are mediated by a neuropeptide mechanism independent of adrenal corticosteroid secretion." (de Wied, 1969)

Subsequent studies confirmed effects on multiple memory domains:

"ACTH 4-10 improved visual memory retention in healthy human subjects when administered intranasally before a visual recognition task. The effect was specific to consolidation rather than encoding, with improved performance evident at 24-hour but not immediate recall." (Pigache & Rigter, 1981)

Melanocortin Receptor Interactions

ACTH 4-10 interacts with melanocortin receptors according to the following selectivity profile:

The lack of MC2R activity is the defining pharmacological feature separating ACTH 4-10 from full-length ACTH. MC2R uniquely requires the ACTH N-terminus (residues 1-3) plus MRAP for activation, while MC3R and MC4R recognize the His-Phe-Arg-Trp core motif present in ACTH 4-10.

Comparison of ACTH Fragments

Neuroprotective Effects

ACTH 4-10 and its analogs demonstrate neuroprotective properties in models of neuronal injury:

• Ischemic neuroprotection — ACTH 4-10 reduces infarct volume in experimental stroke models, likely through MC4R-mediated anti-inflammatory and anti-apoptotic signaling
• Oxidative stress protection — The peptide upregulates antioxidant enzyme expression (SOD, catalase) and reduces lipid peroxidation in neuronal cultures
• Neurite outgrowth — ACTH 4-10 promotes neurite extension in dorsal root ganglion and cortical neuron cultures through MC4R/cAMP/PKA signaling
• Anti-inflammatory CNS effects — Melanocortin receptor activation suppresses microglial activation and reduces neuroinflammatory cytokine production

"Melanocortin peptides including ACTH fragments exert potent anti-inflammatory effects in the central nervous system through MC4R-dependent inhibition of NF-κB signaling in microglia and astrocytes, reducing production of TNF-α, IL-1β, IL-6, and nitric oxide." (Catania et al., 2004)

Related Fragments and Analogs

The structure-activity relationships of ACTH fragments have spawned a family of clinically relevant analogs:

ACTH 4-9 (Met-Glu-His-Phe-Arg-Trp) A hexapeptide retaining most of ACTH 4-10's cognitive activity. Studies show similar effects on attention and memory with slightly different pharmacokinetic properties. The truncation of the C-terminal glycine does not significantly reduce receptor affinity.

Semax (ACTH 4-7-PGP / Met-Glu-His-Phe-Pro-Gly-Pro) The most clinically advanced ACTH fragment analog, Semax extends the ACTH 4-7 core with a C-terminal Pro-Gly-Pro tripeptide that dramatically improves metabolic stability (half-life extended to ~30 minutes vs ~15 minutes for ACTH 4-10). Semax is approved in Russia for acute ischemic stroke, cognitive disorders, and optic nerve disease. Its neuroprotective effects are mediated through both melanocortin receptors and BDNF-dependent neurotrophic signaling.

"Semax (ACTH 4-7-PGP) is a synthetic heptapeptide analog that retains the cognitive-enhancing properties of ACTH 4-10 with improved metabolic stability. Intranasal Semax has demonstrated efficacy in clinical trials for ischemic stroke, producing significant improvement in neurological outcomes when administered within the first 6 hours of symptom onset." (Gusev et al., 2005)

N-Acetyl Semax Amidate A further-modified version of Semax with N-terminal acetylation and C-terminal amidation for enhanced stability and CNS penetration. N-Acetyl Semax Amidate is used in research settings for cognitive enhancement protocols.

Org 2766 (Met(O₂)-Glu-His-Phe-D-Lys-Phe) A modified ACTH 4-9 analog developed by Organon with ~1000x greater potency than ACTH 4-10 in avoidance behavior tests. Org 2766 was studied in clinical trials for diabetic neuropathy and cisplatin-induced neurotoxicity but did not reach market approval.

"Org 2766, a metabolically stable analog of ACTH 4-9, demonstrated 1000-fold greater potency than ACTH 4-10 in behavioral tests and showed partial protection against cisplatin-induced peripheral neuropathy in a controlled clinical trial." (Roberts et al., 1997)

Attention and Information Processing

ACTH 4-10 has demonstrated consistent effects on selective attention in human studies. In a series of controlled trials, ACTH 4-10 improved performance on tasks requiring sustained attention and selective filtering of irrelevant stimuli, without affecting arousal or general alertness.

"ACTH 4-10 selectively enhanced focused attention as measured by Stroop interference and dichotic listening tasks in healthy volunteers, without affecting peripheral arousal indices including heart rate, blood pressure, or skin conductance." (Gaillard & Varey, 1979)

The attentional effects appear to involve modulation of frontal-parietal attention networks. EEG studies have shown that ACTH 4-10 enhances the P300 event-related potential, an electrophysiological marker of attentional resource allocation and working memory updating.

"Administration of an ACTH 4-9 analog to young healthy males enhanced the P300 component of auditory event-related potentials, indicating facilitation of attentional processing and stimulus evaluation independent of motor response preparation." (Smolnik et al., 2000)